$100M to $250M is "sweet spot" for pharma venture funds

06/20/2013 | Genetic Engineering & Biotechnology News

Half of the 20 drugmaker venture capital funds on this list report total resources of between $100 million and $250 million. GlaxoSmithKline, Pfizer, Novartis, Sanofi, Merck and Boehringer Ingleheim are among the drugmakers starting or investing in venture capital funds for new drug discovery.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN